- Development of mRNA Therapeutics: Moderna is advancing its mRNA platform technology to develop new therapeutics for a range of diseases, including cancer, rare genetic diseases, and autoimmune disorders.
- COVID-19 Vaccine Production: Moderna continues to support countries across the world with their vaccination campaigns against COVID-19, and remains the only company to have generated clinical data of its monovalent XBB.1.5 vaccine candidate showing an immune response against XBB sublineages XBB.1.5, XBB.1.16, and XBB.2.3.2, in addition to BA.2.86, EG.5 and FL.1.5.1 variants
- Manufacturing Capacity: Moderna is currently right-sizing its manufacturing footprint in line with the resizing of the COVID-19 vaccine market due to the move from a pandemic to an endemic market. Moderna expects additional capacity at its new mRNA manufacturing facilities in the UK, Canada, and Australia when completed in 2025.
- Research and Development: Moderna is investing in research and development to improve its mRNA technology and develop new therapeutic applications. The company also plans to collaborate with other researchers and organizations to accelerate the discovery of new treatments.
- Global Impact: Moderna’s long-term goal is to revolutionize medicine by using mRNA technology to address unmet medical needs worldwide. The company plans to expand access to its therapies and vaccines globally, with a focus on developing countries and underserved populations.
—
Luis Mustafa Perez
VP Innovation & Operational Excellence
Moderna
As the CMC Vice President of Innovation & Operational Excellence at Moderna, Luis leads the CMC Transformation Office, integrating scalable business processes and advance technologies across functional areas to ensure successful launches and secure vaccine supply through sustainable improvements. Luis has a remarkable track record across Biotechnology, Pharmaceutical, Medical Device, and Consumer industries with over 22 years of experience. He has consistently demonstrated his ability to drive innovation, transformation, and deliver substantial business results.
Significantly, Luis had the honor of leading the 2022 U.S. launches of Moderna’s first COVID-19 booster and pediatric vaccines, impacting millions of lives. He also led the international 2022 COVID vaccines tactical rapid response team and managed the product owners responsible for COVID vaccines and respiratory commercialization.
Before his current role at Moderna, Luis led strategic and operational programs at Johnson & Johnson, where he served as Chief of Staff to the Executive Vice President & Chief Global Supply Chain Officer, managing enterprise-wide strategic projects and activities. He was also responsible for the supply chain team for a J&J startup acquisition, delivering millions in cost savings through portfolio optimization and operational excellence. Over his years in J&J he managed functional teams in Manufacturing Operations, Supply Chain, Enterprise Capabilities, and PMOs.
Luis holds a Master of Business Administration in Information System & Database from the Polytechnic University of Puerto Rico and a Bachelor of Engineering in Industrial Engineering from the University of Puerto Rico-Mayaguez. He has also completed a Leadership program at Harvard University, a Supply Chain Operations program at Penn State University, and a Risk Management program at Stanford University Graduate School of Business. His passion lies in fostering innovation, embracing disruptive ideas to scale and unlock business potential, and driving growth and profitability through innovative operational solutions.
